BREATH BIOPSY OMNI
LIVE

Serial Number

79368676

Owner

Owlstone Medical Limited

Attorney

Feng Shan

Filing Date

Feb 20, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BREATH BIOPSY OMNI Trademark

Serial Number: 79368676 • Registration: 7497789

BREATH BIOPSY OMNI is a trademark filed by Owlstone Medical Limited on February 20, 2023. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Owlstone Medical Limited (15 trademarks)

183 Cambridge Science Park,

Entity Type: 99

Trademark Details

Filing Date

February 20, 2023

Registration Date

September 10, 2024

Published for Opposition

June 25, 2024

Goods & Services

Medical apparatus and instruments for treating cancer, celiac disease, tuberculosis, asthma, inflammatory bowel disease, and fatty liver disease; medical diagnostic apparatus for detecting cancer cells; chemical detection systems and apparatus for medical purposes, namely, analyzers and sampling equipment in the nature of sample collection devices used to collect and analyse liquid, solid and gas samples; medical imaging apparatus; medical and clinical devices in the nature of breath samplers, gas collection tubes used for the collection, recording, concentration and analysis of volatile organic compounds in human breath; medical testing kits for home use in the nature of a medical device for detection of cancer, celiac disease, tuberculosis, asthma, inflammatory bowel disease, and fatty liver disease; medical apparatus for the treatment of respiratory conditions; medical diagnostic apparatus for testing, namely, breath detectors for use to detect disease biomarkers; respiratory sensors for medical purposes; spectrometers for medical purposes; structural and replacement parts and fittings for all the aforesaid; none of the foregoing for use in connection with gynaecological apparatus or instruments; none of the foregoing for use in haemodialysis, haemofiltration, haemodiafiltration and plasma therapy

Medical services; consulting services relating to health care; health care; providing advice and information in the field of health; medical care; medical clinic services; health clinic services; medical health assessment services; health screening services in the field of cancer, celiac disease, tuberculosis, asthma, inflammatory bowel disease, fatty liver disease; diagnostic health screening services in the field of cancer, celiac disease, tuberculosis, asthma, inflammatory bowel disease, fatty liver disease; providing medical information to medical professionals in the form of reports in the field of cancer, celiac disease, tuberculosis, asthma, inflammatory bowel disease, fatty liver disease; medical testing for diagnostic or treatment purposes; medical diagnostic testing services; testing for disease biomarkers for medical purposes; providing advice, information, and consultancy services relating to the aforesaid; none of the foregoing for use in connection with gynaecological apparatus or instruments; none of the foregoing for use in haemodialysis, haemofiltration, haemodiafiltration and plasma therapy.

Downloadable and recorded computer software and computer programs to control collection of medical samples and to perform analysis of medical samples in connection with and a part of medical apparatus and instruments; downloadable and recorded computer application software for hand-held computing devices and to perform analysis of medical samples in connection with and as part of medical apparatus and instruments; downloadable and recorded computer software to perform analysis of medical samples in connection with and as part of medical apparatus and instruments; downloadable and recorded medical diagnostic software for use to control collection of medical samples and to perform analysis of medical samples in connection with and as part of medical apparatus and instruments; diagnostic apparatus for detection of disease bio-markers, not for medical purposes; testing apparatus, not for medical purposes, for use to test calibration of spectrometers and gas detectors; chemical detection systems and apparatus, namely, analyzers and sampling equipment in the nature of mass spectrometers for use to diagnose and monitor diseases in connection with and as part of medical apparatus and instruments; particle detectors; spectrometers; pressure sensors; downloadable and recorded computer software and computer programs for medical purposes for use to diagnose and monitor diseases in connection with and as part of medical apparatus and instruments; structural and replacement parts and fittings for all the aforesaid; all of the aforesaid relating to medical diagnosis and medical analysis: none of the foregoing for use in connection with gynaecological apparatus or instruments; none of the foregoing for use in haemodialysis, haemofiltration, haemodiafiltration and plasma therapy.

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 13, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 15, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 24, 2025 FICS
FINAL DISPOSITION PROCESSED
Feb 23, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 10, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 10, 2024 R.PR
POST PUBLICATION AMENDMENT - ENTERED
Aug 17, 2024 CHPB
ASSIGNED TO PETITION STAFF
Aug 14, 2024 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jul 25, 2024 EPPA
NOTIFICATION PROCESSED BY IB
Jul 1, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 25, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 25, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 11, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 11, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 5, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 17, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 17, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 17, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 17, 2024 TROA
REFUSAL PROCESSED BY IB
Dec 12, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 21, 2023 RFCS
REFUSAL PROCESSED BY MPU
Nov 21, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 18, 2023 RFCR
NON-FINAL ACTION WRITTEN
Nov 17, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 17, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
May 16, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 12, 2023 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
May 8, 2023 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 4, 2023 REPR